Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine
- PMID: 17161812
- DOI: 10.1016/j.intimp.2006.09.020
Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine
Abstract
The therapeutic effects of immunosuppressive drugs are known to deviate largely between patients, but efficient strategies for the differentiation of patients who show clinical resistance to immunosuppressive therapies have not been established. Accordingly, a considerable number of patients receive treatment with immunosuppressive drugs despite the onset of serious side effects and poor responses. Cellular pharmacodynamics of immunosuppressive drugs in vitro using peripheral lymphocytes derived from each patient, an attractive way to distinguish resistant patients, is respected and has been applied to the carrying out of individualized immunosuppressive therapy. In this article, I summarize experimental procedures for assaying immune cell responses to immunosuppressive drugs in vitro, and highlight the relationship between cellular sensitivity to immunosuppressive drugs and the therapeutic efficacy of drugs in organ transplantation and several immunological disorders. I will also overview the molecular mechanisms and genetic bases for cellular and clinical resistance to immunosuppressive drugs. Lastly, the future clinical prospects for the application of in vitro drug sensitivity tests for "patient-tailored" immunosuppressive therapies are discussed.
Similar articles
-
The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy.Front Immunol. 2021 Jan 25;11:618202. doi: 10.3389/fimmu.2020.618202. eCollection 2020. Front Immunol. 2021. PMID: 33569062 Free PMC article.
-
Clinical impact of cyclosporine cellular pharmacodynamics in minimal change nephrotic syndrome.Clin Pharmacol Ther. 2000 Nov;68(5):532-40. doi: 10.1067/mcp.2000.110773. Clin Pharmacol Ther. 2000. PMID: 11103756 Clinical Trial.
-
Clinical relevance of immune monitoring in solid organ transplantation.Int Rev Immunol. 2009;28(3-4):155-84. doi: 10.1080/08830180902929404. Int Rev Immunol. 2009. PMID: 19811320
-
Pharmacogenetics in solid organ transplantation: current status and future directions.Transplant Rev (Orlando). 2008 Jan;22(1):6-20. doi: 10.1016/j.trre.2007.09.002. Transplant Rev (Orlando). 2008. PMID: 18631854 Review.
-
Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Aliment Pharmacol Ther. 2006 Nov 15;24(10):1403-12. doi: 10.1111/j.1365-2036.2006.03147.x. Aliment Pharmacol Ther. 2006. PMID: 17081161 Review.
Cited by
-
The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy.Front Immunol. 2021 Jan 25;11:618202. doi: 10.3389/fimmu.2020.618202. eCollection 2020. Front Immunol. 2021. PMID: 33569062 Free PMC article.
-
Higher Sensitivity of Peripheral Blood Lymphocytes to Endogenous Glucocorticoid in Renal Transplant Recipients Treated With Tacrolimus, as Compared to Those Treated With Cyclosporine.Cell Med. 2012 May 14;3(1-3):75-80. doi: 10.3727/215517912X639423. eCollection 2012 Jan. Cell Med. 2012. PMID: 28058183 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources